VistaGen Therapeutics Announces Peer-Reviewed Publication in The Journal of Pain Highlighting AV-101's Potential for Treating Neuropathic Pain Apr 27, 2017
VistaGen Therapeutics Receives European Patent Office Notice of Intention to Grant European Patent for AV-101 Mar 29, 2017
VistaGen Therapeutics to Ring the Nasdaq Stock Market Closing Bell on Monday, March 13, 2017 Mar 8, 2017
VistaGen Therapeutics Reports Fiscal Third Quarter 2017 Financial Results and Provides Corporate Update Feb 13, 2017
VistaGen Therapeutics Grants Exclusive Sublicense of Cardiac Stem Cell Technologies to BlueRock Therapeutics Dec 14, 2016
VistaGen Therapeutics Appoints Mark A. McPartland Vice President of Corporate Development and Investor Relations Oct 4, 2016
